Adjuvant capecitabine in resected biliary tract cancer: A real-world data from the BILCAP-Real study (ACABi multicenter cohort).
Claire Noé, Julie Henriques, Brice Chanez...
https://pubmed.ncbi.nlm.nih.gov/42520930/Actively Recruiting
Led by GERCOR - Multidisciplinary Oncology Cooperative Group · Updated on 2025-07-23
1350
Participants Needed
32
Research Sites
521 weeks
Total Duration
Researchers are investigating bile duct cancers, a rare group of tumors with generally poor outcomes. This study aims to identify markers that can predict how patients respond to treatments like surgery, chemotherapy, targeted therapy, and local treatments, as well as to evaluate the effectiveness and tolerance of these treatments in current practice. The study includes both retrospective and prospective parts, spanning diagnoses from 2003 to 2030, with a focus on improving treatment decisions for patients. The study is a multi-center cohort observing patients diagnosed between 2003 and 2030. It includes those with intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder adenocarcinoma, excluding ampullomas. Patients are followed for up to 10 years from diagnosis. Data collection involves reviewing treatments such as surgery and chemotherapy, as well as their outcomes and side effects. Past patient data are used for retrospective parts, while new patients diagnosed after 2021 are followed prospectively. Participants will have their medical records reviewed for treatment responses, survival rates, complications, and side effects over a long period. Outcomes measured include overall survival, disease-free survival, progression-free survival, response rates, and postoperative mortality. Genetic studies may also be part of the research with consent. The study allows data use for educational purposes with proper authorization. Participation spans up to 10 years from diagnosis, with follow-up continuing until death or study end.
CONDITIONS
Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study
C
Cindy Neuzillet, Dr
M
Marie-Line Garcia, Dr
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
GERCOR - Multidisciplinary Oncology Cooperative Group
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to diagnosis date
Participants undergo diagnostic evaluations related to their bile duct cancer diagnosis.
1 to 2 visits depending on diagnostic procedures
Duration - Variable duration depending on treatment type and individual response
Participants receive standard treatment for bile duct cancer, including surgery and/or chemotherapy as applicable.
Visits scheduled according to treatment plan (e.g., surgery and chemotherapy visits)
Duration - From day of surgical intervention until 30 days
Participants are monitored for complications and recovery following surgical intervention.
Approximately 1 to 3 post-operative visits
Duration - Up to 10 years from initial diagnosis or until death
Participants are followed for up to 10 years from initial cancer diagnosis to observe overall survival, disease progression, and treatment effects.
Periodic visits or assessments over 10 years as per clinical care
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Claire Noé, Julie Henriques, Brice Chanez...
https://pubmed.ncbi.nlm.nih.gov/42520930/Nicolas Adamus, Julien Edeline, Julie Henriques...
https://pubmed.ncbi.nlm.nih.gov/39897613/GERCOR - Multidisciplinary Oncology Cooperative Group
Lead Sponsor